TY - JOUR
T1 - Inflammation in areas of fibrosis
T2 - The DeKAF prospective cohort
AU - Matas, Arthur J.
AU - Helgeson, Erika S.
AU - Gaston, Robert
AU - Cosio, Fernando
AU - Mannon, Roslyn
AU - Kasiske, Bertram L.
AU - Hunsicker, Lawrence
AU - Gourishankar, Sita
AU - Rush, David
AU - Michael Cecka, J.
AU - Connett, John
AU - Grande, Joseph P.
N1 - Funding Information:
We thank Astellas, Bristol‐Myers Squibb, Novartis, Pfizer, and Sanofi‐Aventis for unrestricted grants that supported this research. We thank Stephanie Taylor for editorial assistance and preparation of the manuscript.
Funding Information:
We thank Astellas, Bristol-Myers Squibb, Novartis, Pfizer, and Sanofi-Aventis for unrestricted grants that supported this research. We thank Stephanie Taylor for editorial assistance and preparation of the manuscript.
Publisher Copyright:
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Inflammation in areas of fibrosis (i-IFTA) in posttransplant biopsy specimens has been associated with decreased death-censored graft survival (DC-GS). Additionally, an i-IFTA score ≥ 2 is part of the diagnostic criteria for chronic active TCMR (CA TCMR). We examined the impact of i-IFTA and t-IFTA (tubulitis in areas of atrophy) in the first biopsy for cause after 90 days posttransplant (n = 598); mean (SD) 1.7 ± 1.4 years posttransplant. I-IFTA, present in 196 biopsy specimens, was strongly correlated with t-IFTA, and Banff i. Of the 196, 37 (18.9%) had a previous acute rejection episode; 96 (49%) had concurrent i score = 0. Unlike previous studies, i-IFTA = 1 (vs 0) was associated with worse 3-year DC-GS: (i-IFTA = 0, 81.7%, [95% CI 77.7 to 85.9%]); i-IFTA = 1, 68.1%, [95% CI 59.7 to 77.6%]; i-IFTA = 2, 56.1%, [95% CI 43.2 to 72.8%], i-IFTA = 3, 48.5%, [95% CI 31.8 to 74.0%]). The association of i-IFTA with decreased DC-GS remained significant when adjusted for serum creatinine at the time of the biopsy, Banff i, ci and ct, C4d and DSA. T-IFTA was similarly associated with decreased DC-GS. Of these indication biopsies, those with i-IFTA ≥ 2, without meeting other criteria for CA TCMR had similar postbiopsy DC-GS as those with CA TCMR. Those with i-IFTA = 1 and t ≥ 2, ti ≥ 2 had postbiopsy DC-GS similar to CA TCMR. Biopsies with i-IFTA = 1 had similar survival as CA TCMR when biopsy specimens also met Banff criteria for TCMR and/or AMR. Studies of i-IFTA and t-IFTA in additional cohorts, integrating analyses of Banff scores meeting criteria for other Banff diagnoses, are needed.
AB - Inflammation in areas of fibrosis (i-IFTA) in posttransplant biopsy specimens has been associated with decreased death-censored graft survival (DC-GS). Additionally, an i-IFTA score ≥ 2 is part of the diagnostic criteria for chronic active TCMR (CA TCMR). We examined the impact of i-IFTA and t-IFTA (tubulitis in areas of atrophy) in the first biopsy for cause after 90 days posttransplant (n = 598); mean (SD) 1.7 ± 1.4 years posttransplant. I-IFTA, present in 196 biopsy specimens, was strongly correlated with t-IFTA, and Banff i. Of the 196, 37 (18.9%) had a previous acute rejection episode; 96 (49%) had concurrent i score = 0. Unlike previous studies, i-IFTA = 1 (vs 0) was associated with worse 3-year DC-GS: (i-IFTA = 0, 81.7%, [95% CI 77.7 to 85.9%]); i-IFTA = 1, 68.1%, [95% CI 59.7 to 77.6%]; i-IFTA = 2, 56.1%, [95% CI 43.2 to 72.8%], i-IFTA = 3, 48.5%, [95% CI 31.8 to 74.0%]). The association of i-IFTA with decreased DC-GS remained significant when adjusted for serum creatinine at the time of the biopsy, Banff i, ci and ct, C4d and DSA. T-IFTA was similarly associated with decreased DC-GS. Of these indication biopsies, those with i-IFTA ≥ 2, without meeting other criteria for CA TCMR had similar postbiopsy DC-GS as those with CA TCMR. Those with i-IFTA = 1 and t ≥ 2, ti ≥ 2 had postbiopsy DC-GS similar to CA TCMR. Biopsies with i-IFTA = 1 had similar survival as CA TCMR when biopsy specimens also met Banff criteria for TCMR and/or AMR. Studies of i-IFTA and t-IFTA in additional cohorts, integrating analyses of Banff scores meeting criteria for other Banff diagnoses, are needed.
KW - Interstitial fibrosis and tubular atrophy
KW - classification systems: Banff classification
KW - clinical research/practice
KW - kidney transplantation/nephrology
KW - pathology/histopathology
UR - http://www.scopus.com/inward/record.url?scp=85083427612&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083427612&partnerID=8YFLogxK
U2 - 10.1111/ajt.15862
DO - 10.1111/ajt.15862
M3 - Article
C2 - 32185865
AN - SCOPUS:85083427612
SN - 1600-6135
VL - 20
SP - 2509
EP - 2521
JO - American Journal of Transplantation
JF - American Journal of Transplantation
IS - 9
ER -